Outlook Wealth Advisors LLC Has $357,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Outlook Wealth Advisors LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 707 shares of the company’s stock after acquiring an additional 64 shares during the period. Outlook Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $357,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Mediolanum International Funds Ltd grew its holdings in shares of IDEXX Laboratories by 52.5% during the third quarter. Mediolanum International Funds Ltd now owns 27,269 shares of the company’s stock valued at $13,933,000 after buying an additional 9,388 shares during the last quarter. Legacy Capital Group California Inc. bought a new position in IDEXX Laboratories in the 3rd quarter valued at about $750,000. Values First Advisors Inc. boosted its stake in IDEXX Laboratories by 8.9% during the 3rd quarter. Values First Advisors Inc. now owns 2,324 shares of the company’s stock valued at $1,174,000 after purchasing an additional 189 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in IDEXX Laboratories by 42.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 119,001 shares of the company’s stock worth $60,122,000 after purchasing an additional 35,750 shares in the last quarter. Finally, IFM Investors Pty Ltd raised its stake in shares of IDEXX Laboratories by 0.3% in the third quarter. IFM Investors Pty Ltd now owns 18,947 shares of the company’s stock worth $9,572,000 after purchasing an additional 56 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IDXX. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. JPMorgan Chase & Co. cut their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Piper Sandler cut their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Finally, BTIG Research initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Stock Down 0.2 %

IDEXX Laboratories stock opened at $451.41 on Friday. The firm has a 50 day moving average price of $484.62 and a 200-day moving average price of $489.32. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a market capitalization of $37.16 billion, a P/E ratio of 44.69, a P/E/G ratio of 4.03 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing the consensus estimate of $2.88 by ($0.44). The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. IDEXX Laboratories’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the company posted $2.67 earnings per share. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.